Challenging Market Conditions Impact Lenzing AG's Q3 Results

Lenzing AG has reported stable revenue for the first nine months of 2025 despite market volatility. The revenue increased slightly to EUR 1.97 billion. The EBITDA rose by 29.1% to EUR 340.4 million due to the sale of surplus emission allowances and biological asset valuation. Despite this, Q3 faced headwinds, resulting in impairment losses of EUR 82.1 million in Indonesia, impacting EBIT negatively.

The company's strategic focus aims for value-generating growth, operational efficiency, and high-margin products like TENCEL™, VEOCEL™, and LENZING™ ECOVERO™. A strategic review of the Indonesian site is underway to secure this growth and EUR 45 million in annual savings expected by 2027.

Financially, Lenzing maintains a strong position with EUR 993 million liquidity, complemented by recent financing measures, though net financial debt improved to EUR 1.4 billion. Despite challenges, the EBITDA outlook remains positive for 2025.